<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01864915</url>
  </required_header>
  <id_info>
    <org_study_id>DMED 1578-13 HOOKEY</org_study_id>
    <secondary_id>9427-D2773-21C</secondary_id>
    <nct_id>NCT01864915</nct_id>
  </id_info>
  <brief_title>Prucalopride + Prucalopride Booster vs. Prucalopride + Picosalax Booster for the Colon Capsule</brief_title>
  <official_title>Prucalopride + Prucalopride Booster vs. Prucalopride + Picosalax Booster for the Colon Capsule</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Queen's University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hotel Dieu Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Janssen Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Queen's University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Colon capsule endoscopy is a new technology that is a noninvasive method of examining the&#xD;
      large bowel. The bowel preparation required for this test differs from colonoscopy in that it&#xD;
      needs to clean the colon but also needs to provide propulsion. Most published studies have&#xD;
      used medications as part of their regime that are not available in parts of North America&#xD;
      (ex. sodium phosphate) and have shown poor test completion, bowel preparation and polyp&#xD;
      detection rates.&#xD;
&#xD;
      Objective: In this study a bowel preparation for the colon capsule is proposed that uses&#xD;
      medications approved for use in Canada that may provide a better preparation quality and&#xD;
      better completion rates.&#xD;
&#xD;
      Methods: Patients who are being referred for a colonoscopy will be recruited to participate&#xD;
      in the study. They will all receive split-dose polyethylene glycol (PEG) for bowel&#xD;
      preparation. They will be randomized to receive either 1) Prucalopride 2mg daily for four&#xD;
      days, 2) Prucalopride 2mg daily for four days plus a Prucalopride booster, or 3) Prucalopride&#xD;
      2mg for four days plus 1 and 1/2 sachets of Picosalax boosters for the colon capsule study.&#xD;
      The day after the colon capsule they will drink PEG ( 2 Liters) at 5am -or approx 4hrs prior&#xD;
      to procedure time and return for a colonoscopy. The colon capsule results will be reviewed by&#xD;
      two endoscopists experienced in video capsule endoscopy who will assess the bowel preparation&#xD;
      using a previously defined scale and examine for polyps. We propose that administering&#xD;
      Prucalopride daily for 4 days will increase intestinal motility and improve colon capsule&#xD;
      completion rates and a booster dose of Picosalax will improve colon capsule completion rates&#xD;
      compared to prucalopride by itself.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Colon capsule endoscopy is a new technology that is a noninvasive method of examining the&#xD;
      large bowel. The bowel preparation required for this test differs from colonoscopy in that it&#xD;
      needs to clean the colon but also needs to provide propulsion. Most published studies have&#xD;
      used medications as part of their regime that are not available in parts of North America&#xD;
      (ex. sodium phosphate) and have shown poor test completion, bowel preparation and polyp&#xD;
      detection rates.&#xD;
&#xD;
      Objective: In this study a bowel preparation for the colon capsule is proposed that uses&#xD;
      medications approved for use in Canada that may provide a better preparation quality and&#xD;
      better completion rates.&#xD;
&#xD;
      Methods: Patients who are being referred for a colonoscopy will be recruited to participate&#xD;
      in the study. They will all receive split-dose polyethylene glycol (PEG) for bowel&#xD;
      preparation. They will be randomized to receive either 1) Prucalopride 2mg daily for four&#xD;
      days, 2) Prucalopride 2mg daily for four days plus a Prucalopride booster, or 3) Prucalopride&#xD;
      2mg for four days plus 1 and 1/2 sachets of Picosalax boosters for the colon capsule study.&#xD;
      The day after the colon capsule they will drink PEG ( 2 Liters) at 5am -or approx 4hrs prior&#xD;
      to procedure time and return for a colonoscopy. The colon capsule results will be reviewed by&#xD;
      two endoscopists experienced in video capsule endoscopy who will assess the bowel preparation&#xD;
      using a previously defined scale and examine for polyps. We propose that administering&#xD;
      Prucalopride daily for 4 days will increase intestinal motility and improve colon capsule&#xD;
      completion rates and a booster dose of Picosalax will improve colon capsule completion rates&#xD;
      compared to prucalopride by itself&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2013</start_date>
  <completion_date type="Actual">October 2014</completion_date>
  <primary_completion_date type="Actual">October 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Double (Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To assess the quality of the bowel preparations</measure>
    <time_frame>Day of colon capsule procedure and day of colonoscopy</time_frame>
    <description>Colon capsule bowel prep assessed with previously used scale completed by designated gastroenterologists.&#xD;
Colonoscopy bowel prep assessed by completion of Aronchick Scale by endoscopist performing procedure.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tolerance of Bowel Preparation with survey</measure>
    <time_frame>Day of colonoscopy</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gastric, small bowel and colon transit time</measure>
    <time_frame>Day of colon capsule</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Bowel Cleansing</condition>
  <condition>Colon Capsule Completion Times</condition>
  <arm_group>
    <arm_group_label>No Booster-low dose prucalopride booster</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>low dose prucalopride booster arm</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Prucalopride Booster-high dose prucalopride booster</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>additional 2mg prucalopride at time of capsule ingestion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Picosalax Booster Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One sachet of Picosalax 2hrs after capsule ingestion and 1/2 sachet at 4 hrs after swallowing colon capsule.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prucalopride</intervention_name>
    <description>Prucalopride 2mg daily starting three days before the colon capsule study (total of 4 doses with the last at 0800hrs on day of colon capsule study)</description>
    <arm_group_label>No Booster-low dose prucalopride booster</arm_group_label>
    <arm_group_label>Picosalax Booster Arm</arm_group_label>
    <arm_group_label>Prucalopride Booster-high dose prucalopride booster</arm_group_label>
    <other_name>RESTORAN</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Colon Capsule</intervention_name>
    <description>Colon capsule procedure performed day prior to colonoscopy, at 0800 hrs on day 4.</description>
    <arm_group_label>No Booster-low dose prucalopride booster</arm_group_label>
    <arm_group_label>Picosalax Booster Arm</arm_group_label>
    <arm_group_label>Prucalopride Booster-high dose prucalopride booster</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients between the ages of 18-75 being referred for colonoscopy&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  symptoms of dysphagia or any problems with swallowing, bowel obstruction or ileus,&#xD;
             known stricture or fistula, inflammatory bowel disease, previous small or large bowel&#xD;
             surgery, severe gastroparesis or motility disorder, severe renal impairment ( defined&#xD;
             as lab test result eGFR ie. estimated Glomerular Filtration Rate less than 55 within&#xD;
             three months of study), congestive heart failure (NYHA III or IV), ischemic heart&#xD;
             disease (acute event in the last 6mths), decompensated cirrhosis or severe hepatic&#xD;
             dysfunction (ascites or known lab test INR&gt;2), history of serious arrhythmia or any&#xD;
             other severe and clinically unstable concomitant disease (eg. lung disease,&#xD;
             neurological or psychiatric disorder, cancer, AIDS and other endocrine disorder)&#xD;
             ,diabetics on treatment with insulin or hypoglycemic, pregnant or nursing women,&#xD;
             galactose intolerance (since the tablets contain lactose monohydrate, patients with&#xD;
             rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or&#xD;
             glucose/galactose malabsorption must not take this medicinal product.) or known&#xD;
             hypersensitivity to the drug or to any ingredient in the formulation (each 2mg tablet&#xD;
             contains prucalopride 2 mg. Nonmedicinal ingredients: tablet core: lactose&#xD;
             monohydrate, microcrystalline cellulose, colloidal silicon dioxide, and magnesium&#xD;
             stearate; coating: hypromellose, lactose monohydrate, triacetin, titanium dioxide,&#xD;
             macrogol 3000, iron oxide red, iron oxide yellow, and FD&amp;C Blue No. 2 Aluminum Lake)&#xD;
             Females of child bearing potential who are unwilling to use appropriate birth control&#xD;
             methods during the study will not be able to participate in this clinical trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lawrence Hookey</last_name>
    <role>Principal Investigator</role>
    <affiliation>Queen's University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hotel Dieu Hospital</name>
      <address>
        <city>Kingston</city>
        <state>Ontario</state>
        <zip>K7L 5V7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <study_first_submitted>May 25, 2013</study_first_submitted>
  <study_first_submitted_qc>May 25, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 30, 2013</study_first_posted>
  <last_update_submitted>February 14, 2017</last_update_submitted>
  <last_update_submitted_qc>February 14, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">February 16, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Queen's University</investigator_affiliation>
    <investigator_full_name>Dr. Lawrence Hookey</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>colon capsule</keyword>
  <keyword>bowel preparation</keyword>
  <keyword>booster</keyword>
  <keyword>prucalopride</keyword>
  <keyword>picosalax</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prucalopride</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>final analysis dataset shared with Janssen Inc (study sponsor)</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

